-
Questcor Pharmaceuticals Plunges on U.S. Government Investigation
Monday, September 24, 2012 - 3:24pm | 326Read More...Last week, Questcor Pharmaceuticals (NASDAQ: QCOR) was among the most volatile stocks on the Nasdaq exchange after insurer Aetna (NYSE: AET) said that it was limiting coverage of the company's Athcar Gel drug used for the treatment of multiple sclerosis. The news sent QCOR plunging last Wednesday,...
-
Warner Chilcott Receives 2nd PIV Challenge for Asacol (WCRX)
Tuesday, June 29, 2010 - 8:49am | 138Read More...On June 28th Warner Chilcott (NASDAQ:WRCX) announced it had received a Paragraph IV certification from Par Pharmaceuticals challenging Warner Chilcott's 400mg dose of Asacol. This is the second filing, after Roxane Laboratories. Oppenheimer analysts John Newman and Christopher Holterhoff do not see...
-
Oppenheimer Upbeat About Questcor Pharmaceuticals (QCOR)
Thursday, June 10, 2010 - 10:37am | 219Read More...Oppenheimer analysts John Newman and Christopher Holterhoff maintained their Outperform rating for shares of Questcor Pharmaceuticals Inc (Nasdaq: QCOR), with a price target of $14 per share. The analysts said that although they expect a positive decision from the FDA for the use of Questcor...
-
Oppenheimer Rates Eurand N.V. (EURX) Outperform
Monday, May 17, 2010 - 11:22am | 192Read More...Oppenheimer & Co. analysts John Newman and Christopher Holterhoff maintained their Outperform rating for shares of Eurand N.V. (Nasdaq: EURX), with a price target of $12 per share. The analysts increased their estimates for 2010 through 2012 due to lower estimated operating expenses. They said...
-
Oppenheimer Maintains Salix Pharmaceuticals (SLXP) Outperform Rating
Wednesday, March 10, 2010 - 10:05am | 151Read More...Oppenheimer analysts John Newman and Christopher Holterhoff maintained their Outperform rating and price target of $40 for shares of Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP). The analysts said that they expect an FDA decision on XIFAXAN in HE by March 24 2010, with a launch date by late May and...
